Jump to content

Search the Community

Showing results for tags 'PCOS'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


  • The LuPUS Message Board
    • Announcements
    • What is the LuPUS Message Board?
    • A Welcome to New Members
    • User Problems
    • Links
  • Medical
    • Medical News 2003
    • Medical News 2004
    • Medical News 2005
    • Medical News 2006
    • Medical News 2007
    • Medical News 2008
    • Medical News 2009
    • Medical News 2010
    • Medical News 2011
    • Medical News 2012
    • Medical News 2013
    • Medical News 2014
    • Medical News 2015
    • Medical News 2016
    • Medical News 2017
    • Medical News 2018
    • Medical News 2019
    • Medical News 2020
    • Medical News 2021
    • Coronavirus: COVID-19
    • Medication & Therapy
    • Lupus and Pregnancy
    • Sjögren’s syndrome
    • Lymphoedema
    • Marginal Zone Lymphoma
  • Non-Medical
    • LuPUS Message Board
  • Public
    • Guest & Test Messages
    • Free Offers
    • Contributors


  • Admin
  • Admin
  • Changes To My Diet For Health Reasons


There are no results to display.

There are no results to display.

Find results in...

Find results that contain...

Date Created

  • Start


Last Updated

  • Start


Filter by number of...


  • Start





Website URL





Surname (Last or Family name)

First name

Date of Birth




Found 2 results

  1. Screen for Anxiety, Mood Disorders in All Women With PCOS: Study By Megan Brooks NEW YORK (Reuters Health) Dec 16 - A new systematic review and meta-analysis shows that women with polycystic ovary syndrome (PCOS) are at higher risk for anxiety and depression. "Clinicians should screen all women with the diagnosis of PCOS for anxiety disorders," first author Dr. Anuja Dokras of the University of Pennsylvania Medical Center, Philadelphia, told Reuters Health. "The association between anxiety disorders and PCOS is not well known." Women with PCOS often have low self-esteem, poor body image, and fears about future health problems, including infertility, and perceived lack of effective treatment, all of which may make them anxious, Dr. Dokras and colleagues said in a November 29 online report in Fertility and Sterility. Yet, only "limited data" exist on the prevalence of anxiety disorders in women with PCOS, the authors say. From among 613 relevant articles they found nine studies from 2004-2010 that met their strict selection criteria. Four studies had data on the prevalence of generalized anxiety symptoms in women with clearly defined PCOS and well-selected control women. The prevalence of anxiety was 20% in women with PCOS (42 of 206) vs. 4% in controls (8 of 204). "A variety of validated screening tools were used in the studies reporting the higher prevalence of anxiety symptoms," the authors note. Women with PCOS had nearly a sevenfold increased risk of generalized anxiety symptoms (pooled odds ratio, 6.88). One study that matched controls on age and body mass index found 13-fold greater odds of anxiety with PCOS. Most PCOS patients and control subjects in the reviewed studies were overweight or obese. Of the five studies that reported average anxiety scores, three had significantly higher anxiety scores in women with PCOS compared with control women. There was little information about other anxiety disorders, such as social phobia, panic attack, and obsessive compulsive disorder. Two of three studies reported a higher prevalence of social phobia in women with PCOS and one of two studies reported a higher prevalence of obsessive compulsive disorder. Dr. Dokras and colleagues had previously reported that 35% of women with PCOS suffered from depression, a substantially higher rate than the 11% in control women. Added to that, Dr. Dokras said, the new data suggest that "clinicians should now screen all women with PCOS for both anxiety and mood disorders" using validated screening tools. Those found to have a mood disorder should be "referred for appropriate evaluation and/or use of psychologic and pharmacologic treatments," the researchers say. They say more studies are needed to clearly define the prevalence of anxiety disorders in adolescents with PCOS, "given the early age of onset and chronic recurring nature of anxiety disorders." "Future studies," they advise, "should be aimed at evaluating the association of common PCOS-specific characteristics, such as hyperandrogenism and infertility, with anxiety symptoms and disorders. This will help us to better understand why anxiety is more prevalent in women with PCOS and thereby to individualize therapies." SOURCE: http://bit.ly/swahV3 Fertil Steril 2011. Reuters Health Information © 2011
  2. BMJ 2011; 343:d6407 doi: 10.1136/bmj.d6407 (Published 13 October 2011) Cite this as: BMJ 2011; 343:d6407 Editorial Polycystic ovary syndrome Nick S Macklon, professor of obstetrics and gynaecology +Author AffiliationsN.S.Macklon@soton.ac.uk Independently increases the risk of adverse pregnancy and birth outcomes Polycystic ovary syndrome is a common condition. The reported incidence varies between 3% and 15% of women of reproductive age, depending on the population studied and the diagnostic criteria applied,1 which include hyperandrogenism, anovulation, and polycystic ovaries. Rising obesity rates are likely to increase the incidence further. The implications of this for those who care for women in pregnancy are highlighted in the linked cohort study, in which Roos and colleagues assess the risk of adverse pregnancy outcomes in women with a diagnosis of polycystic ovary syndrome, taking maternal characteristics and assisted reproductive technology into account (doi:10.1136/bmj.d6309).2 Although polycystic ovary syndrome is associated with increased long term risks of type 2 diabetes and cardiovascular disease, most affected women present initially with anovulatory infertility. Weight loss can resolve this, but it is often difficult to achieve and medical treatments are usually required. Most will respond to anti-oestrogen treatment, and those who do not usually ovulate when given exogenous gonadotrophins.3 However, in vitro fertilisation is being offered earlier in the treatment pathway, using single embryo transfer to mitigate the risk of multiple pregnancy associated with ovulation induction. Until recently the focus of care has been on achieving pregnancy safely, but evidence is increasing that once women with polycystic ovary syndrome get pregnant they may be at increased risk of perinatal and neonatal morbidity. A systematic review in 2007 showed an association between polycystic ovary syndrome and increased risks of gestational diabetes, pre-eclampsia, preterm birth, and perinatal mortality,4 which was confirmed by a recent meta-analysis.5 However, until now it has been unclear whether the reported adverse outcomes derive from polycystic ovary syndrome itself, the associated obesity, or the fertility treatments and resulting multiple pregnancies. Roos and colleagues tackle this question by linking data related to singleton births reported in the Swedish medical birth register to the Swedish patient register by means of the unique identifying number issued to each citizen at birth.2 The large and consistently defined study and control cohorts allowed for correction for the effect of body mass index and fertility treatment and reduced the heterogeneity in study groups that complicated interpretation of the previously published meta-analyses. The authors show a clear association between polycystic ovary syndrome and a significantly increased risk of pregnancy being complicated by pre-eclampsia (adjusted odds ratio 1.45, 95% confidence interval 1.24 to 1.69), very preterm birth (2.21, 1.69 to 2.90), gestational diabetes (2.32, 1.88 to 2.88), and babies large for gestational age (1.39, 1.19 to 1.62). So where do we go from here? The clinical implications are clear. Pregnant women with polycystic ovary syndrome should be considered at increased risk of perinatal complications, should be monitored accordingly, and should have their babies delivered in hospital. However, several questions arise. Given the broad clinical presentation of polycystic ovary syndrome and broad definitions encompassed by the authors (who used three versions of the international classification of diseases), should all women with polycystic ovary syndrome be considered at similar risk? Could the specific phenotype of polycystic ovary syndrome determine individual risks in pregnancy? A recent study suggested that women with polycystic ovary syndrome characterised by ovulatory dysfunction and hyperandrogenism are at increased risk compared with those characterised by normal ovulatory function.6Larger prospective studies are needed to elucidate which components of polycystic ovary syndrome may be predictive of specific complications such as gestational diabetes or pre-eclampsia. If women at particular risk can be identified, what interventions can improve outcomes? Current practice focuses on optimising health before pregnancy or reducing insulin resistance during pregnancy. The association between obesity and perinatal morbidity is widely recognised, and periconceptional weight loss is advocated despite the paucity of data to show that it improves pregnancy outcomes in women with polycystic ovary syndrome. Insulin sensitisers such as metformin seem to be safe for both mother and fetus, and although cohort studies have indicated a beneficial effect on risk of developing gestational diabetes and pre-eclampsia,7 a recent placebo controlled randomised trial showed no clear effect on the incidence of pre-eclampsia, preterm delivery, gestational diabetes, or birth weight.8 The power of the study to discern differences in specific complications was, however, limited, and no subgroup analysis was done on specific phenotypes. It is clear that women with polycystic ovary syndrome should be considered “high risk” obstetric patients and that midwives, general practitioners, and obstetricians should monitor these women as such. Ideally, prepregnancy assessments of glucose tolerance, lipid profile, and blood pressure should be carried out.9 However, more evidence is required to support the use of currently used interventions designed to reduce perinatal risk, and this requires a greater understanding of the different polycystic ovary syndrome phenotypes and the underlying mechanisms by which this common condition alters pregnancy outcomes. Clues come from studies which indicate that pregnancy may constitute a “stress test” for risk of developing cardiovascular disease later in life. Associations between increased insulin resistance in pregnancy, perinatal hypertensive disorders, and later hypertensive disease have been reported and may reflect endothelial dysfunction.10 Although pregnancy may impose additional risks to certain women with polycystic ovary syndrome, it may also afford the opportunity to screen for their risk of long term cardiovascular complications. Notes Cite this as: BMJ 2011;343:d6407 Footnotes [*]Research, doi:10.1136/bmj.d6309 [*] Competing interests: None declared. [*] Provenance and peer review: Commissioned; not externally peer reviewed. References [*]1.↵ Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG2006;113:1210-7. [CrossRef][Medline][Web of Science] [*]2.↵ Roos N, Kieler H, Sahlin L, Ekman-Ordeberg G, Falconer H, Stephansson O. Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study.BMJ2011;343:d6309. [Abstract/FREE Full text] [*]3.↵ Eijkemans MJ, Imani B, Mulders AG, Habbema JD, Fauser BC. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod2003;18:2357-62. [Abstract/FREE Full text] [*]4.↵ Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update2006;12:673-83. [Abstract/FREE Full text] [*]5.↵ Kjerulff LE, Sanchez Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a meta-analysis. Am J Obstet Gynecol2011;204:558.e1-6. [Medline] [*]6.↵ Palomba S, Falbo A, Russo T, Tolino A, Orio F, Zullo F. Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes. Fertil Steril2010;94:1805-11. [CrossRef][Medline] [*]7.↵ Khattab S, Mohsen IA, Aboulfoutouh I, Ashmawi H, Mohsen M, van Wely M, et al. Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. Gyn Endocrinol2011; published online 19 Jan. [*]8.↵ Vanky E, Stridsklev S, Heimstad R, Romundstad P, Skogøy K, Kleggetveit O, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab2010;95:E448-55. [Abstract/FREE Full text] [*]9.↵ Norman RJ. Textbook of periconceptional medicine. Macklon NS, Greer IA, Steegers EAP, eds. Informa, 2009. [*]10.↵ Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?BMJ2002;325:157-60. [url=http://www.bmj.com/cgi/ijlink?linkType=FULL&journalCode=bmj&resid=325/7356/157][FREE Full text]
  • Create New...

Important Information